All In Biotech

Drug Trial Radar · NCT01057537

UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events

A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.

Last checked: Nov 20, 2026Latest source record: Nov 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,004 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,004

Actual

Start

Jun 2010

Primary completion

Jul 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Imperial College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission; Imperial College Healthcare NHS Trust; Royal College of Surgeons, Ireland; UMC Utrecht; The George Institute; Public Health Foundation of India; Dr. Reddy's Laboratories Limited, India
First posted
Jan 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with established cardiovascular disease need secondary prevention that addresses multiple risk factors. Complexity \& cost confer particularly difficult barriers to uptake of treatment; recovery from a stroke or heart attack typically necessitates multiple drugs for cholesterol, blood pressure and platelet function. A low-cost, fixed-dose, once-daily combination polypill, the Red Heart Pill, has been formulated by Dr Reddy's Laboratories. UMPIRE will evaluate whether provision of this polypill compared with usual medications improves adherence and clinical outcomes among high-risk patients in Europe and India. The results will be used to develop recommendations for equitable access.

Conditions

  • Cardiovascular Diseases

Interventions

  • polypillDrug

    The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill): Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.

  • Usual cardiovascular medicationsDrug

    Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adherence to medication; self-reported current use of antiplatelet, statin and combination (≥ 2) blood pressure lowering therapyTime frame: End of trial follow-up
  2. Change in blood pressureTime frame: End of trial follow-up
  3. Change in LDL cholesterolTime frame: End of trial follow-up

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • George Institute Australia

    Sydney, New South Wales, Australia

  • George Institute for International Health - India

    Hyderabad, India

  • Public Health Foundation of India

    New Dehli, India

  • Centre for Chronic Disease Control

    New Delhi, India

  • Royal College of Surgeons in Ireland Research Institute

    Dublin, Ireland

  • University Medical Center Utrecht

    Utrecht, Heidelberglaan 100, Netherlands

  • Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College London

    Paddington, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.